Australian Regulator Explains How To Comply With Advertising Rules While Meeting Continuous Disclosure Obligations

Companies should avoid focusing only on the positive qualities of a therapeutic good or omitting or downplaying the negative qualities such as possible side effects, according to new guidance on therapeutic goods advertising and Australian Securities Exchange announcements.

Chest of doctor wearing a white coat with hands around a heart-shaped Australian flag.
Australia's regulator has issue new guidance for companies that develop therapeutic goods • Source: Shutterstock

“Works fastest,” “the best,” and “life changing.” These are examples of the statements that Australia’s Therapeutic Goods Administration says health care product companies should avoid using if they want to comply with the requirements for advertising therapeutic goods when they make announcements to comply with their continuous disclosure obligations.

Listed and unlisted companies have continuous disclosure obligations under the Corporations Act 2001 to ensure market integrity and investor protection...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Asia

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

 

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.

South Korean Health Ministry Sees Benefits Of Pre-Regulatory Review

 
• By 

A system of pre-regulatory review consultations for innovative drugs and devices in South Korea has contributed to the accelerated development of such products.

FDA Blocks Some Olympus Endoscopes From Entering US

 

After multiple warning letters and safety communications, the US FDA has decided to block the import of certain endoscopes from Olympus. In total, the agency’s action pertains to 58 device models manufactured by the Japanese firm used in urinary, respiratory, abdominal and pelvic procedures.

New EU Rules Limit Chinese Participation In Medtech Procurement

 

From June 30, new European Commission rules will attempt to redress an imbalance in medtech trade between the EU and the People’s Republic of China.

More from Geography

EUDAMED Notice Anticipated By September As Commission Optimizes Operations

 

The last steps are taking place leading to the launch of the EU’s medical device database, EUDAMED.

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

 

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.

Commission Decision Launches Pediatric And Rare Disease Expert Group

 

A revised annex to the original decision also outlines expert remuneration limits and introduces further changes.